Abstract:Eleven-nineteen leukemia (ENL) protein is a histone acetylation reader essential for disease maintenance in acute leukemias, in particular, the mixed-lineage leukemia (MLL)-rearranged leukemia. In this study, we carried out high-throughput screening of a small-molecule library to identify inhibitors for the ENL YEATS domain. Structure–activity relationship studies of the hits and structure-based inhibitor design led to two compounds, 11 and 24, with IC50 values below 100 nM in inhibiting the ENL–acetyl-H3 interaction. Both compounds, and their precursor compound 7, displayed strong selectivity toward the ENL YEATS domain over all other human YEATS domains. Moreover, 7 exhibited on-target inhibition of ENL in cultured cells and a synergistic effect with the bromodomain and extraterminal domain inhibitor JQ1 in killing leukemia cells. Together, we have developed selective chemical probes for the ENL YEATS domain, providing the basis for further medicinal chemistry-based optimization to advance both basic and translational research of ENL.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00367?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00367</a>.Overview of screen assay development, IC50 of top compounds, SPR and NMR data, cell growth inhibition, cell permeability assay, CETSA result of 7 in HeLa, qRT-PCR data, synergistic effect of 7 and JQ1 in MV4-11, molecular docking models of compounds bound to AF9 and ENL YEATS domains, HPLC traces for lead compounds, and table of the structure and IC50 of compounds from HTS with IC50 below 5 μM (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00367/suppl_file/jm1c00367_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00367/suppl_file/jm1c00367_si_002.csv">CSV</a>)Docking models (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00367/suppl_file/jm1c00367_si_003.zip">ZIP</a>)This article has not yet been cited by other publications.

Lead Optimization of Small Molecule ENL YEATS Inhibitors to Enable In Vivo Studies: Discovery of TDI-11055

Small-molecule inhibition of the acyl-lysine reader ENL as a strategy against acute myeloid leukemia

Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia

Discovery of Selective Small-Molecule Inhibitors for the ENL YEATS Domain

Phage-Assisted, Active Site-Directed Ligand Evolution with a Genetically Encoded Nε-Butyryl-L-Lysine to Identify a Cellularly Potent and Selective Inhibitor for the ENL YEATS Domain as an Anti-Leukemia Agent

Conformational-Design-Driven Discovery of EZM0414: A Selective, Potent SETD2 Inhibitor for Clinical Studies

Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Optimization and Biological Evaluation of Novel 1H-Pyrrolo[2,3-c]pyridin Derivatives As Potent and Reversible Lysine Specific Demethylase 1 Inhibitors for the Treatment of Acute Myelogenous Leukemia

Design, synthesis, and biological evaluation of adenosine derivatives targeting DOT1L and HAT as anti-leukemia agents

Structure-guided Development of YEATS Domain Inhibitors by Targeting Π-Π-π Stacking

Design, Synthesis, and Evaluation of a Novel Dual Fms-Like Tyrosine Kinase 3/stem Cell Factor Receptor (Flt3/c-Kit) Inhibitor for the Treatment of Acute Myelogenous Leukemia

Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions Between DOT1L and MLL-AF9/MLL-ENL.

Design, Synthesis of Novel Benzimidazole Derivatives As ENL Inhibitors Suppressing Leukemia Cells Viability Via Downregulating the Expression of MYC

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)

Design and Synthesis of Selective FLT3 Inhibitors Via Exploration of Back Pocket II

Property Focused Structure-Based Optimization Of Small Molecule Inhibitors Of The Protein-Protein Interaction Between Menin And Mixed Lineage Leukemia (Mll)

Discovery and Anticancer Screening of Novel Oxindole-Based Derivative Bearing Pyridyl Group as Potent and Selective Dual FLT3/CDK2 Kinase Inhibitor

Structure-Based Drug Design of Novel Triaminotriazine Derivatives As Orally Bioavailable IDH2R140Q Inhibitors with High Selectivity and Reduced Herg Inhibitory Activity for the Treatment of Acute Myeloid Leukemia.

Discovery of Potent, Selective, and Orally Available IRE1α Inhibitors Demonstrating Comparable PD Modulation to IRE1 Knockdown in a Multiple Myeloma Model

Combining Structure- and Property-Based Optimization to Identify Selective FLT3-ITD Inhibitors with Good Antitumor Efficacy in AML Cell Inoculated Mouse Xenograft Model.